The Claim
In very high-risk patients, combination lipid-lowering therapy with statins and ezetimibe is associated with a lower risk of stroke compared to statin monotherapy, with an odds ratio of 0.83 (95% CI: 0.75–0.91), indicating a statistically significant reduction in stroke incidence with dual therapy.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
Taking both a statin and ezetimibe together may help prevent strokes better than taking just a statin, especially in people at very high risk.
See the scientific wording
Combination lipid-lowering therapy with statins and ezetimibe is associated with a lower risk of stroke compared to statin monotherapy in very high-risk patients, with an odds ratio of 0.83 (95% CI: 0.75–0.91), indicating a statistically significant association between dual therapy and reduced stroke incidence.
What the research says
1 studyThe study found that taking statins plus ezetimibe lowers the chance of having a stroke more than taking statins alone, just like the claim says.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.